Yun-peng Lİ, Hong-cheng SONG, Xiao-li MA, Le-jian HE, Wei-ping ZHANG

Relationship between tumor viability during treatment and the clinical outcomes of patients with bladder/prostate rhabdomyosarcoma: a single-center experience

Background. To analyze the relationship between tumor viability in specimens retrieved at second-look procedures (SLPs) and clinical outcomes in patients with bladder/prostate rhabdomyosarcoma (BP RMS). Methods. We retrospectively analyzed patients’ characteristics, times between diagnoses and SLPs, types of SLPs, the pathological findings, and clinical outcomes between January 2003 and May 2014. Results. A total of 29 patients underwent at least one SLP before completing chemotherapy, including 24 boys and 5 girls. The mean age was 36 months. No patients with clinical/radiographic complete responses (CRs) had viable tumor cells and 7/18 patients (38.9%) without CR had no viable tumor cells. Seven patients experienced tumor relapse, progression, and metastasis, and three of these survived. Five-year event-free survival (EFS) rates were 88.5% in 18 patients without viable tumor at SLPs and 54.5% in 11 patients with viable tumor (Cox proportional hazards adjusted P=0.045). The respective five-year overall survival (OS) rates were 94.1% and 72.7% (Cox proportional hazards adjusted P=0.175). Conclusions. EFS was increased in patients with BP RMS having no viable tumor cells; however, OS was comparable in patients with and without viable tumor cells. Patients who achieved CR during the treatment generally had no viable tumor cells

PDF

___

1. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE.Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 2011;170: e243-e251.

2. Dasgupta R, Fuchs J, Rodeberg D. Rhabdomyosarcoma. Semin Pediatr Surg 2016; 25: 276-283.

3. Rodeberg DA, Anderson JR, Arndt CA, et al. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/ prostate: combined results from the Children’s Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee. Int J Cancer 2011; 128: 1232-1239.

4. Vaarwerk B, van der Lee JH, Breunis WB, et al. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: a report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. Cancer 2018; 124: 1016-1024.

5. Rosenberg AR, Anderson JR, Lyden E, et al. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children’s Oncology Group. Eur J Cancer 2014; 50: 816-823.

6. Raney B, Stoner J, Anderson J, et al; Soft-Tissue Sarcoma Committee of the Children’s Oncology Group. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children’s oncology group. J Pediatr Surg 2010; 45: 2160-2168.

7. Godzinski J, Flamant F, Rey A, Praquin MT, Martelli H. Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study. Med Pediatr Oncol 1994; 22: 22-26.

8. Cecchetto G, Carretto E, Bisogno G, et al. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: a report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer 2008; 51: 593-597.

9. Hays DM, Raney RB, Crist WM, et al. Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: a report from the Intergroup Rhabdomyosarcoma Study. J Pediatr Surg 1990; 25: 1100-1105.

10. Stein R, Frees S, Schroder A, et al. Radical surgery and different types of urinary diversion in patients with rhabdomyosarcoma of bladder or prostate--a single institution experience. J Pediatr Urol 2013; 9(6 Pt A): 932-939.

11. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610-630.

12. Parham DM, Barr FG.Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 2013; 20: 387-397.

13. Arndt CA, Hammond S, Rodeberg D, Qualman S. Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: results from IRS IV. J Pediatr Hematol Oncol 2006; 28: 563- 567.

14. Wu HY.The surgical management of paediatric bladder and prostate rhabdomyosarcoma. Arab J Urol 2013; 11: 40-46.